Marine engaged in CREATING bilolgical weapon

Marine Corps personnel engaged in CREATING
biological
weapon (that George Merck,)


In 1998 in Rochester, New York, I met a former
military man, PFC Donald Bentley, who gave me a
document and told me: "I was in the US Army, and
I was
trained in bacteriological warfare. We were
handling a
bomb filled with brucellosis, only it wasn’t
brucellosis; it was a Brucella toxin in
crystalline
form. We were spraying it on the Chinese and
North
Koreans."

He showed me his certificate listing his training
in
chemical, biological and radiological warfare.
Then he
showed me 16 pages of documents given to him by
the US
military when he was discharged from the service.
They
linked brucellosis with multiple sclerosis, and
stated
in one section: "Veterans with multiple
sclerosis, a
kind of creeping paralysis developing to a degree
of
10% or more disability within two years after
separation from active service, may be presumed
to be
service-connected for disability compensation.
Compensation is payable to eligible veterans
whose
disabilities are due to service." In other words:
"If
you become ill with multiple sclerosis, it is
because
you were handling this Brucella, and we will give
you
a pension. Don’t go raising any fuss about it."
In
these documents, the government of the United
States
revealed evidence of the cause of multiple
sclerosis,
but they didn’t make it known to the public—or to
your
doctor.

Many doctors don’t know about this mycoplasma
disease
agent because it was developed by the US military
in
biological warfare experimentation and it was not
made
public. This pathogen was patented by the United
States military and Dr Shyh-Ching Lo. I have a
copy of
the documented patent from the US Patent
Office.(1)
Endnotes :
1. "Pathogenic Mycoplasma", US Patent No.
5,242,820,
issued September 7, 1993. Dr Lo is listed as the
Inventor" and the American Registry of Pathology,
Washington, DC, is listed as the "Assignee".




In a 1949 report, Drs Kyger and Haden suggested
"the
possibility that multiple sclerosis might be a
central
nervous system manifestation of chronic
brucellosis".
Testing approximately 113 MS patients, they found
that
almost 95% also tested positive for Brucella.(5)
We
have a document from a medical journal, which
concludes that one out of 500 people who had
brucellosis would develop what they call
neurobrucellosis; in other words, brucellosis in
the
brain, where the Brucella settles in the lateral
ventrides—where the disease multiple sclerosis is
basically located.6

The title page of a genuine US Senate Study,
declassified on February 24, 1977, shows that
George
Merck, of the pharmaceutical company, Merck Sharp
&
Dohme (which now makes cures for diseases that at
one
time it created), reported in 1946 to the US
Secretary
of War that his researchers had managed "for the
first
time" to "isolate the disease agent in
crystalline
form".3



Contamination of Camp Detrick Lab Workers
A 1948 New England Journal of Medicine report
titled
"Acute Brucellosis Among Laboratory Workers"
shows us
how actively dangerous this agent is.7 The
laboratory
workers were from Camp Detrick, Frederick,
Maryland,
where they were developing biological weapons.
Even
though these workers had been vaccinated, wore
rubberised suits and masks and worked through
holes in
the compartment, many of them came down with this
awful disease because it is so absolutely and
terrifyingly infectious.

The article was written by Lt Calderone Howell,
Marine
Corps Captain Edward Miller, Marine Corps, Lt
Emily
Kelly, United States Naval Reserve; and Captain
Henry
Bookman. They were all military personnel engaged
in
making the disease agent Brucella into a more
effective biological weapon


   * Location: that George Merck,
M
Merck & Co., Inc. is a global research-driven
pharmaceutical company dedicated to putting
patients
first.
Newsroom
FDA Accepts Two Supplemental New Drug
Applications to
Expand the U.S. Labeling for JANUVIA™

Action Expected by Mid-October on New Indications
for
First and Only DPP-4 Inhibitor

WHITEHOUSE STATION, N.J., Feb. 15, 2007 - Merck &
Co.,
Inc. today announced that the U.S. Food and Drug
Administration (FDA) has accepted for standard
review
two supplemental New Drug Applications (sNDAs)
for
JANUVIA™ (sitagliptin), and the Company expects
FDA
action on both sNDAs by mid-October.

One sNDA is filed in support of a proposed new
indication for the use of JANUVIA, as an adjunct
to
diet and exercise, in combination with metformin
as
initial therapy to improve glycemic control. The
other
sNDA is filed in support of two proposed new
indications for use of JANUVIA, as an adjunct to
diet
and exercise, as add-on therapy to a sulfonylurea
when
the single agent alone does not provide adequate
glycemic control and as add-on therapy to the
combination of a sulfonylurea plus metformin when
dual
therapy does not provide adequate glycemic
control.

JANUVIA is currently indicated for use as
monotherapy
and as add-on therapy to either of two other
types of
oral diabetes medications, metformin or
thiazolidinediones (TZDs), to improve blood sugar
(glucose) control in patients with type 2
diabetes
when diet and exercise are not enough. The
recommended
dose of JANUVIA is 100 mg once daily. JANUVIA
should
not be used in patients with type 1 diabetes or
for
the treatment of diabetic ketoacidosis, as it
would
not be effective in these settings. In clinical
trials, JANUVIA demonstrated an overall incidence
of
side effects comparable to placebo. The most
common
side effects reported with JANUVIA (greater than
or
equal to 5 percent and higher than placebo) were
stuffy or runny nose and sore throat, upper
respiratory infection, and headache.

"If these sNDAs are approved, the expanded
labeling
will include indications for use of JANUVIA as
initial
therapy with metformin and as add-on to any of
the
three most commonly prescribed classes of oral
antihyperglycemic agents," said John Amatruda,
M.D.,
vice president, clinical research, Merck & Co.,
Inc.
"These data further support the broad utility of
JANUVIA as an important treatment option for
patients
with type 2 diabetes."

Phase III data supporting two sNDAs
The proposed new indication of JANUVIA in
combination
with metformin as initial therapy is supported by
a
24-week, factorial study in 1,091 randomized
patients
with type 2 diabetes. Results of this study were
presented for the first time at the annual
meeting of
the European Association for the Study of
Diabetes in
September 2006.

The study showed a significant mean
placebo-subtracted
reduction in A1C1 of 2.1 percent from a mean
baseline
A1C of 8.7 percent (primary analysis of all
patients
treated, p >0.001) in the patients treated with
JANUVIA 50 mg twice daily combined with metformin
1,000 mg twice daily (n=178). In the same study,
66
percent of patients treated with JANUVIA 50 mg
twice
daily combined with metformin 1,000 mg twice
daily
achieved goal A1C levels of <7 percent compared
to 38
percent of patients treated with metformin 1,000
mg
twice daily alone (p <0.01). Even in those
patients
receiving a lower dose of metformin (JANUVIA 50
mg
twice daily and metformin 500 mg twice daily,
n=183),
significant A1C placebo-subtracted reductions
(1.6
percent, p <0.001) and greater goal attainment
(43
percent vs. 23 percent with metformin 500 mg
twice
daily alone, p <0.01) were observed.

In the study, initial therapy of JANUVIA and
metformin
was generally well tolerated and showed no
meaningful
differences in tolerability compared to metformin
alone. Side effects of JANUVIA 50 mg twice daily
and
metformin 1,000 mg twice daily compared to
metformin
1,000 mg twice daily alone included diarrhea (9
percent vs. 10 percent, respectively), nausea (6
percent vs. 8 percent), abdominal pain/discomfort
(3
percent vs. 5 percent) and vomiting (3 percent
vs. 1
percent).

The proposed new indications of adding JANUVIA to
a
sulfonylurea or to a sulfonylurea plus metformin
are
supported by a 24-week study examining the
efficacy
and safety of JANUVIA in 441 patients with type 2
diabetes who had inadequate glycemic control on a
sulfonylurea alone or a sulfonylurea plus
metformin.
Results from this Phase III study were submitted
to a
major medical meeting for presentation later this
year.

Dosing of JANUVIA
The recommended dose of JANUVIA is 100 mg once
daily,
with or without food, for all approved
indications. No
dosage adjustment is needed for patients with
mild to
moderate hepatic insufficiency or in patients
with
mild renal insufficiency (CrCl greater than or
equal
to 50 mL/min). To achieve plasma concentrations
of
JANUVIA similar to those in patients with normal
renal
function, lower dosages are recommended in
patients
with moderate and severe renal insufficiency as
well
as in ESRD patients requiring hemodialysis. For
patients with moderate renal insufficiency (CrCl
greater than or equal to 30 to < 50 mL/min), the
dose
of JANUVIA is 50 mg once daily. For those with
severe
renal insufficiency (CrCl < 30 mL/min) or with
ESRD
requiring dialysis, the dose of JANUVIA is 25 mg
once
daily. Because there is a need for dosage
adjustment
based upon renal function, assessment of renal
function is recommended prior to initiation of
JANUVIA
and periodically thereafter.

Selected cautionary information
JANUVIA should be used during pregnancy only if
clearly needed. Caution should be exercised when
JANUVIA is administered to a nursing woman.
Because
elderly patients are more likely to have
decreased
renal function, care should be taken in dose
selection
in the elderly and it may be useful to assess
renal
function in these patients prior to initiating
dosing
and periodically thereafter. The incidence of
selected
gastrointestinal adverse reactions in patients
treated
with JANUVIA was as follows: abdominal pain
(JANUVIA,
2.3 percent; placebo, 2.1 percent), nausea (1.4
percent, 0.6 percent) and diarrhea (3.0 percent,
2.3
percent).

Expanding clinical trial program for JANUVIA
Merck's clinical development program for JANUVIA
is
robust and continues to expand with 43 studies
completed or under way, and ten more studies set
to
begin this year. There are more than 7,600
patients in
the Company's clinical studies with about 4,700
of
these patients being treated with JANUVIA.
Additionally, about 1,100 patients have been
treated
with JANUVIA for more than a year.

About Merck
Merck & Co., Inc. is a global research-driven
pharmaceutical company dedicated to putting
patients
first. Established in 1891, Merck discovers,
develops,
manufactures and markets vaccines and medicines
to
address unmet medical needs. The company devotes
extensive efforts to increase access to medicines
through far-reaching programs that not only
donate
Merck medicines but help deliver them to the
people
who need them. Merck also publishes unbiased
health
information as a not-for-profit service. For more
information, visit www.merck.com.

Merck forward-looking statement
This press release contains "forward-looking
statements" as that term is defined in the
Private
Securities Litigation Reform Act of 1995. These
statements are based on management's current
expectations and involve risks and uncertainties,
which may cause results to differ materially from
those set forth in the statements. The
forward-looking
statements may include statements regarding
product
development, product potential or financial
performance. No forward-looking statement can be
guaranteed, and actual results may differ
materially
from those projected. Merck undertakes no
obligation
to publicly update any forward-looking statement,
whether as a result of new information, future
events,
or otherwise. Forward-looking statements in this
press
release should be evaluated together with the
many
uncertainties that affect Merck's business,
particularly those mentioned in the cautionary
statements in Item 1 of Merck's Form 10-K for the
year
ended Dec. 31, 2005, and in its periodic reports
on
Form 10-Q and Form 8-K, which the Company
incorporates
by reference.

JANUVIA™ is a registered trademark for Merck &
Co.,
Inc.

1A1C is a measure of a person’s average blood
glucose
over a two- to three-month period.
# # #